The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- Iterative Health Closes $77 Million Series C to Accelerate the Future of Clinical Research (Business Wire)
- Private Equity vs. Independent Medicine: When Wall Street Enters the Exam Room (Working Healthcare – the Podcast Fixing Healthcare)
- Artificial Intelligence Is Not the End of the Physician (JAMA)
- Charted: The most (and least) burned out physician specialties (Advisory Board)
- Growth, practice value and mergers: A strategic guide for physicians (Medical Economics)
- The potential ‘litigation wave’ headed for GI (Becker’s GI & Endoscopy)
- Groundbreaking new study shows real-time AI platform better at diagnosing cancer than biopsy (UMass Chan Medical School)
- Investigational endoscopic therapy maintains weight after GLP-1 discontinuation (GI & Hepatology News)
